<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lenalidomide is approved for red blood cell (RBC) transfusion-dependent <z:hpo ids='HP_0001903'>anemia</z:hpo> due to low or intermediate-1 (int-1) risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) associated with a chromosome 5q deletion with or without additional cytogenetic abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>We report results of a multicenter, phase 2 trial evaluating lenalidomide therapy for transfusion-dependent patients with low- or int-1-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> without deletion 5q </plain></SENT>
<SENT sid="2" pm="."><plain>Eligible patients had 50,000/mm(3) or more platelets and required 2 U or more RBCs within the previous 8 weeks; 214 patients received 10 mg oral lenalidomide daily or 10 mg on days 1 to 21 of a 28-day cycle </plain></SENT>
<SENT sid="3" pm="."><plain>The most common grade 3/4 adverse events were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (30%) and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (25%) </plain></SENT>
<SENT sid="4" pm="."><plain>Using an intention-to-treat analysis, 56 (26%) patients achieved transfusion independence (TI) after a median of 4.8 weeks of treatment with a median duration of TI of 41.0 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>In patients who achieved TI, the median rise in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> was 32 g/L (3.2 g/dL; range, 10-98 g/L [1.0-9.8 g/dL]) from baseline </plain></SENT>
<SENT sid="6" pm="."><plain>A 50% or greater reduction in transfusion requirement occurred in 37 additional patients, yielding a 43% overall rate of hematologic improvement (TI response + ||&gt;or= 50% reduction in transfusion requirement) </plain></SENT>
<SENT sid="7" pm="."><plain>Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who lack the deletion 5q karyotypic abnormality </plain></SENT>
</text></document>